DK3285809T3 - Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. - Google Patents

Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. Download PDF

Info

Publication number
DK3285809T3
DK3285809T3 DK16719655T DK16719655T DK3285809T3 DK 3285809 T3 DK3285809 T3 DK 3285809T3 DK 16719655 T DK16719655 T DK 16719655T DK 16719655 T DK16719655 T DK 16719655T DK 3285809 T3 DK3285809 T3 DK 3285809T3
Authority
DK
Denmark
Prior art keywords
immunction
infections
inhibitors
cancer
treatment
Prior art date
Application number
DK16719655T
Other languages
English (en)
Inventor
Kevin R Webster
Vikas Goel
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Application granted granted Critical
Publication of DK3285809T3 publication Critical patent/DK3285809T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Genetics & Genomics (AREA)
DK16719655T 2015-04-20 2016-04-15 Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. DK3285809T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562150140P 2015-04-20 2015-04-20
US201562260917P 2015-11-30 2015-11-30
PCT/US2016/027870 WO2016172010A1 (en) 2015-04-20 2016-04-15 Inhibitors of immune checkpoint modulators for use in treating cancer and infections

Publications (1)

Publication Number Publication Date
DK3285809T3 true DK3285809T3 (da) 2019-11-18

Family

ID=55861220

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16719655T DK3285809T3 (da) 2015-04-20 2016-04-15 Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.

Country Status (9)

Country Link
US (2) US10702526B2 (da)
EP (1) EP3285809B1 (da)
JP (1) JP6681919B2 (da)
KR (2) KR20180004740A (da)
CN (1) CN107750167B (da)
AU (1) AU2016252038B2 (da)
CA (1) CA2982984C (da)
DK (1) DK3285809T3 (da)
WO (1) WO2016172010A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016252038B2 (en) 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
AU2016343687A1 (en) * 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
EA034440B1 (ru) * 2015-10-29 2020-02-07 Эффектор Терапьютикс, Инк. СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
WO2017087808A1 (en) * 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
TW201831479A (zh) * 2017-01-20 2018-09-01 德商拜耳製藥公司 經取代二氫咪唑并吡啶二酮
UY37594A (es) * 2017-02-07 2018-08-31 Univ Saitama Medical Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer
JP7167041B2 (ja) 2017-02-10 2022-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
AU2018220840A1 (en) * 2017-02-14 2019-09-19 Effector Therapeutics, Inc. Piperidine-substituted Mnk inhibitors and methods related thereto
EP3391907B8 (en) 2017-04-20 2020-03-04 iOmx Therapeutics AG Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof
CA3064000A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
JP7352473B2 (ja) 2017-06-21 2023-09-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル がん細胞を標的化するキメラ抗原受容体のための方法および組成物
CA3079607A1 (en) 2017-10-19 2019-04-25 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of mnk1 and mnk2
WO2019088016A1 (ja) * 2017-10-30 2019-05-09 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物および免疫療法剤が組み合わせて投与される医薬組成物
EP3749352A1 (en) * 2018-02-05 2020-12-16 Tesaro Inc. Pediatric niraparib formulations and pediatric treatment methods
CN109266731A (zh) * 2018-08-23 2019-01-25 窦帅杰 Tim-3与NF90的相互作用在预防或治疗病毒感染产品中的应用
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
DK3873903T3 (da) 2018-10-31 2024-04-02 Gilead Sciences Inc Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
EP3890789A4 (en) * 2018-12-03 2022-12-14 Fusion Pharmaceuticals Inc. COMBINATION RADIOIMMUNOCONJUGATE AND CHECKPOINT INHIBITOR THERAPY
JP7797198B2 (ja) * 2018-12-21 2026-01-13 オーエスイー・イミュノセラピューティクス ヒトｐｄ－１に対する二機能性分子
WO2020171138A1 (ja) 2019-02-20 2020-08-27 学校法人 埼玉医科大学 放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー
CN109833480B (zh) * 2019-03-22 2021-09-07 中国科学院上海巴斯德研究所 靶向nk细胞免疫检查点治疗感染性疾病的方法
EP3947640A4 (en) 2019-04-02 2022-12-14 The Brigham & Women's Hospital, Inc. PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
JP2021008453A (ja) 2019-07-02 2021-01-28 エフェクター・セラピューティクス，インコーポレーテッド 翻訳阻害剤およびその使用
WO2021003194A1 (en) * 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Eif4e inhibitors for use as immune checkpoint modulators and related methods
US20220257571A1 (en) * 2019-07-10 2022-08-18 Funpació Hospital Universitari Vall D'hebron - Institut De Recerca Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
CA3144018A1 (en) * 2019-08-05 2021-02-11 The Board Of Trustees Of The Leland Stanford Junior University Manipulation and use of antigen-specific regulatory t cells
CN114555820A (zh) * 2019-09-05 2022-05-27 帕姆基因有限公司 用于预测非小细胞肺癌患者对pd-1或pd-l1免疫检查点抑制剂的响应的激酶活性签名
KR20220113390A (ko) 2019-11-13 2022-08-12 다이호야쿠힌고교 가부시키가이샤 Lsd1 억제제를 사용하여 lsd1-관련 질환 및 장애를 치료하는 방법
HRP20241540T1 (hr) 2019-11-18 2025-01-03 Jumbo Drug Bank Co., Ltd. Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
JP7772700B2 (ja) * 2019-12-19 2025-11-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 神経膠芽腫を処置するための方法
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
WO2022206758A1 (zh) * 2021-03-29 2022-10-06 药捷安康(南京)科技股份有限公司 多激酶抑制剂的联合应用
JP7638031B2 (ja) * 2021-05-08 2025-03-03 成都嘉葆薬銀医薬科技有限公司 ピロロトリアジン系化合物の塩形、その結晶形及びその製造方法
CN114315774B (zh) * 2022-01-04 2023-05-09 山东第一医科大学(山东省医学科学院) Psf蛋白抑制剂、药物组合物及其应用
WO2024017229A1 (zh) * 2022-07-19 2024-01-25 成都嘉葆药银医药科技有限公司 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
AU2006261082B2 (en) 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2010036404A2 (en) 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
WO2010055072A2 (en) * 2008-11-12 2010-05-20 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating a mnk
CA2836203A1 (en) 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
ES2625854T3 (es) 2011-06-01 2017-07-20 Bayer Intellectual Property Gmbh Aminoimidazopiridazinas sustituidas
EP2723748B1 (en) 2011-06-22 2016-10-12 Bayer Intellectual Property GmbH Heterocyclyl aminoimidazopyridazines
WO2013019906A1 (en) * 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
WO2013041634A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
WO2013087581A1 (en) 2011-12-12 2013-06-20 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9777004B2 (en) 2012-03-29 2017-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CA2869212A1 (en) 2012-04-04 2013-10-10 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
ES2591129T3 (es) 2012-05-21 2016-11-25 Bayer Pharma Aktiengesellschaft Tienopirimidinas
WO2013174743A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
WO2013174735A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2900671A1 (en) 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
EP2900670A1 (en) 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
ES2635262T3 (es) * 2012-11-09 2017-10-03 Evotec International Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
JP2015537017A (ja) 2012-11-19 2015-12-24 バイエル ファーマ アクチエンゲゼルシャフト アミノイミダゾピリダジン類
GB2508652A (en) 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
JP2016506943A (ja) 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類
US20160159816A1 (en) 2013-02-01 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
CA2899662A1 (en) 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
HK1212699A1 (zh) 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物
US9675612B2 (en) 2013-03-06 2017-06-13 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
JP6720075B2 (ja) 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌のための併用療法
DK3013805T3 (da) 2013-06-28 2018-04-23 Evotec Int Gmbh Sulfoximin-substituerede quinazoliner og deres anvendelse som MNK1- og/eller MNK2-kinasehæmmere
PE20160125A1 (es) * 2013-07-08 2016-03-17 Bayer Pharma AG Pirazolpiridinas sustituidas
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
AU2016252038B2 (en) 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections

Also Published As

Publication number Publication date
CN107750167B (zh) 2021-05-25
AU2016252038B2 (en) 2021-08-12
CA2982984A1 (en) 2016-10-27
US20210046074A1 (en) 2021-02-18
AU2016252038A1 (en) 2017-11-02
EP3285809A1 (en) 2018-02-28
JP6681919B2 (ja) 2020-04-15
JP2018513172A (ja) 2018-05-24
CA2982984C (en) 2023-10-17
NZ736852A (en) 2024-07-26
WO2016172010A1 (en) 2016-10-27
KR102891799B1 (ko) 2025-11-26
US20160303124A1 (en) 2016-10-20
US10702526B2 (en) 2020-07-07
KR20240038145A (ko) 2024-03-22
EP3285809B1 (en) 2019-09-11
CN107750167A (zh) 2018-03-02
KR20180004740A (ko) 2018-01-12

Similar Documents

Publication Publication Date Title
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3331900T3 (da) Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3227237T3 (da) Indretning og anvendelse deraf til uv-bearbejdning af fluider
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3521289T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
DK3842429T3 (da) Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3122358T3 (da) Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK4339615T3 (da) Anti-PD-1-antistof til anvendelse i behandlingen af kræft
IL261047A (en) Taf1 inhibitors for the therapy of cancer
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3113782T3 (da) Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer